Skip to main content
Fig. 5 | BMC Ophthalmology

Fig. 5

From: One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient

Fig. 5

Mean change in the best-corrected visual acuity and central subfield macular thickness. a Mean change in the best-corrected visual acuity and b central subfield macular thickness of the patients in the treatment-naïve group. c Mean change in the best-corrected visual acuity and central subfield macular thickness of the patients in the pre-treated group. d central subfield macular thickness of the patients in the pre-treated group

Back to article page
\